FDA May Revisit Antidepressant “Black Box” Suicidality Warning
Executive Summary
FDA will monitor emerging data on suicides and antidepressants as it becomes available to determine if an uptick in suicides among adolescents is associated with the decline in prescriptions for antidepressants that followed the addition of a "black box" warning to labeling for the products
You may also be interested in...
Class Labeling For Anti-epileptics Embraces Lessons From Antidepressants
Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.
Class Labeling For Anti-epileptics Embraces Lessons From Antidepressants
Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.
Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions
FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31